Congress mandates free lung cancer screening for Medicaid, Medicare, and insured Americans

What it does

This bill requires Medicaid to cover annual lung cancer screening with no patient cost-sharing for people meeting U.S. Preventive Services Task Force guidelines, expands Medicaid coverage of tobacco-cessation counseling and drugs to all Medicaid enrollees (not just pregnant women), eliminates prior-authorization requirements for lung cancer screening under Medicare and private insurance, and funds a $10 million/year education campaign (2028–2032) to inform patients and providers about screening eligibility.

Why we flagged it

The bill's operative mechanism is a mandate that public and private insurers cover lung cancer screening and tobacco-cessation services without cost-sharing or administrative barriers. It is a public-health measure, not a market intervention or subsidy.

What the text implies

• Expansion of tobacco-cessation coverage to all Medicaid enrollees (not just pregnant women) may increase demand for pharmacotherapy and counseling services, potentially straining provider capacity in rural or underserved areas.
• The bill ties screening eligibility to USPSTF guidelines as of March 9, 2021, freezing the standard; future guideline updates that broaden screening populations will not automatically trigger coverage unless Congress amends the bill.
• Prior-authorization elimination may reduce administrative burden on providers but could increase screening volume and associated costs to state Medicaid budgets, though the bill does not appropriate federal funds to offset state costs.
• The Comptroller General study (Section 6) may identify underscreened populations (firefighters, veterans, women under 50) but the bill contains no mechanism to expand coverage if the study recommends it—a future legislative action would be required.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicaid and Medicare beneficiaries gain access to evidence-based preventive screening at no cost and without administrative delay (prior authorization). Tobacco-cessation support expands to all Medicaid enrollees, removing a prior restriction to pregnant women. Private insurance enrollees also benefit from the prior-authorization ban. Early detection of lung cancer improves survival outcomes.

Who stands to gain

• Diagnostic imaging providers (CT scan facilities)
• Pulmonology and primary care practices
• Pharmaceutical manufacturers (tobacco-cessation drugs)
• Behavioral health and counseling service providers

Named in the bill

Centers for Medicare & Medicaid Services (CMS), U.S. Preventive Services Task Force (USPSTF), Department of Health and Human Services (HHS), Medicaid State Plans, Medicare Advantage organizations, Private health insurers, Comptroller General of the United States

Where it stands

1 cosponsor: 1 Democrats.

• May 19, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• May 19, 2026 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance. (text: CR S2377-2379)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $120,000 in lobbying spend. A filing names 54 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.

• American Lung Association — $120,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.